Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) reported Q2 adjusted EPS loss of $0.94 per share, better than the Zacks Consensus Estimate of a $1.04 loss. Revenue was $0.02 million, far below the consensus estimate, down from $0.73 million a year earlier. The article cites a Zacks Rank #2 (Buy) and upcoming consensus outlook of -$1.07 EPS on $1.86 million revenue for the next quarter.
How this was made
The 30-second read
Why it matters
EPS beat (+9.62% surprise) but revenues missed massively (down to $0.02M and 98.75% below consensus). The next actionable driver is management’s earnings-call commentary and any subsequent changes to near-term and full-year consensus estimates.
Market read
Traders get a concrete earnings datapoint (EPS beat) alongside a major revenue miss, implying a two-sided setup where guidance and estimate revisions will determine whether the stock sustains gains.
What to watch
The article highlights estimate revisions and a Zacks Rank #2, but does not quantify guidance changes; the market may instead anchor on the magnitude of the revenue miss and cash runway concerns not discussed here.
Background
The article summarizes Celldex’s Q2 adjusted results versus Zacks Consensus and discusses how estimate revisions may influence near-term stock movement.
Ticker impact
Celldex reported Q2 adjusted EPS of -$0.94, beating the -$1.04 consensus, while revenue was $0.02M versus a $0.73M year-ago and far below estimates.
Likely choppy trading around the earnings call, with upside bias only if guidance and revenue trajectory improve.
The article provides concrete EPS and revenue outcomes versus consensus, but does not include new guidance numbers; it flags that management commentary and estimate revisions will drive the stock’s immediate move.
Market effects
Reinforces that small-cap biopharma can see EPS beats without revenue traction, keeping investors focused on pipeline and near-term commercialization signals.
No specific regional spillover described.
No global macro or cross-border catalyst described.
Counterpoint
EPS can be less informative for early-stage biopharma if revenue is structurally low; traders may fade the EPS beat unless management provides credible revenue/pipeline milestones.
Key entities
- companyCelldex Therapeutics
Biopharmaceutical company reporting Q2 adjusted EPS and revenue versus consensus, with near-term outlook tied to earnings-call commentary and estimate revisions.
